Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment

Naoki Nishio, Stan van Keulen, Nynke S. van den Berg, Guolan Lu, Ethan P. LaRochelle, Scott C. Davis, Brock A. Martin, Shayan Fakurnejad, Quan Zhou, Andrew C. Birkeland, Michael J. Kaplan, Vasu Divi, A. Dimitrios Colevas, Brian W. Pogue, Eben L. Rosenthal

Research output: Contribution to journalArticle

Abstract

Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.

Original languageEnglish (US)
JournalHead and Neck
DOIs
StateAccepted/In press - Jan 1 2019
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Coloring Agents
Fluorescence
Antibodies
Equipment and Supplies
Neoplasms
Selection Bias
Optical Imaging
Frozen Sections
Area Under Curve
Technology
Growth

Keywords

  • EGFR
  • fluorescence dosimetry
  • fluorescence-guided tissue preselection
  • head and neck cancer
  • panitumumab

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment. / Nishio, Naoki; van Keulen, Stan; van den Berg, Nynke S.; Lu, Guolan; LaRochelle, Ethan P.; Davis, Scott C.; Martin, Brock A.; Fakurnejad, Shayan; Zhou, Quan; Birkeland, Andrew C.; Kaplan, Michael J.; Divi, Vasu; Colevas, A. Dimitrios; Pogue, Brian W.; Rosenthal, Eben L.

In: Head and Neck, 01.01.2019.

Research output: Contribution to journalArticle

Nishio, N, van Keulen, S, van den Berg, NS, Lu, G, LaRochelle, EP, Davis, SC, Martin, BA, Fakurnejad, S, Zhou, Q, Birkeland, AC, Kaplan, MJ, Divi, V, Colevas, AD, Pogue, BW & Rosenthal, EL 2019, 'Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment', Head and Neck. https://doi.org/10.1002/hed.25964
Nishio, Naoki ; van Keulen, Stan ; van den Berg, Nynke S. ; Lu, Guolan ; LaRochelle, Ethan P. ; Davis, Scott C. ; Martin, Brock A. ; Fakurnejad, Shayan ; Zhou, Quan ; Birkeland, Andrew C. ; Kaplan, Michael J. ; Divi, Vasu ; Colevas, A. Dimitrios ; Pogue, Brian W. ; Rosenthal, Eben L. / Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment. In: Head and Neck. 2019.
@article{811fd017720f42289af155196b6bb642,
title = "Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment",
abstract = "Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95{\%} CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.",
keywords = "EGFR, fluorescence dosimetry, fluorescence-guided tissue preselection, head and neck cancer, panitumumab",
author = "Naoki Nishio and {van Keulen}, Stan and {van den Berg}, {Nynke S.} and Guolan Lu and LaRochelle, {Ethan P.} and Davis, {Scott C.} and Martin, {Brock A.} and Shayan Fakurnejad and Quan Zhou and Birkeland, {Andrew C.} and Kaplan, {Michael J.} and Vasu Divi and Colevas, {A. Dimitrios} and Pogue, {Brian W.} and Rosenthal, {Eben L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hed.25964",
language = "English (US)",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment

AU - Nishio, Naoki

AU - van Keulen, Stan

AU - van den Berg, Nynke S.

AU - Lu, Guolan

AU - LaRochelle, Ethan P.

AU - Davis, Scott C.

AU - Martin, Brock A.

AU - Fakurnejad, Shayan

AU - Zhou, Quan

AU - Birkeland, Andrew C.

AU - Kaplan, Michael J.

AU - Divi, Vasu

AU - Colevas, A. Dimitrios

AU - Pogue, Brian W.

AU - Rosenthal, Eben L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.

AB - Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.

KW - EGFR

KW - fluorescence dosimetry

KW - fluorescence-guided tissue preselection

KW - head and neck cancer

KW - panitumumab

UR - http://www.scopus.com/inward/record.url?scp=85073973363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073973363&partnerID=8YFLogxK

U2 - 10.1002/hed.25964

DO - 10.1002/hed.25964

M3 - Article

C2 - 31571335

AN - SCOPUS:85073973363

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

ER -